Compare Devon Energy Corp (DVN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Devon Energy Corp trades at $50.03 (market cap $55.23B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Devon Energy Corp is far larger — about 7.3× Spyre Therapeutics Inc. Common Stock's market cap, and Devon Energy Corp pays a 2.55% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| DVN | SYRE | |
|---|---|---|
Market Cap | $55.23B | $7.52B |
Volume | 10,032,111 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $52.07 | $108.92 |
52-Week Low | $31.74 | $22.18 |
Typical Hold Time | 136 Days | 0 Days |
Enterprise Value | $65.97B | $6.52B |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $49.92, up 1.96% with strong bullish technical signals from moving averages. The stock shows attractive valuation metrics including a P/E of 10.92 and P/S of 1.79, while maintaining solid profitability with 16.67% net margins. Recent activist investor pressure for strategic alternatives and potential asset sales create catalysts, though the company faces earnings volatility with mixed quarterly results including a Q1 miss but Q2 beat.
DVN presents value opportunity with 25% upside to consensus target of $62.53, supported by 72% analyst buy ratings. Key risks include oil price sensitivity and execution on asset sales, while the improving cash flow trend and Permian Basin focus provide fundamental support. The combination of reasonable valuation and strategic optionality makes DVN compelling for energy investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
